Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory

This article was originally published in The Pink Sheet Daily

Executive Summary

Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.

You may also be interested in...

House Members Propose Primatene Mist Inventory Clearance Sale

The House Energy and Power Subcommittee July 18 will discuss draft legislation that would require EPA to allow sales of the remaining inventory of Armstrong Pharmaceutical’s CFC-propelled epinephrine inhalers, Primatene Mist.

FDA Should Release Existing Supply Of Primatene Mist OTC Asthma Inhaler, Rep. Says

Lawmakers seek to restore the availability of Primatene Mist while the absence of an alternative OTC asthma remedy persists.

Primatene Mist Chances To Remain On Market Dwindle With Senate Vote

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts